Lonza adds microbial plant for Servier partnership

Credit: REUTERS/ARND WIEGMANN

Swiss contract manufacturer Lonza Group is adding a mid-scale microbial facility to supply France's Laboratoires Servier with active pharmaceutical ingredient for acute lymphoblastic leukaemia therapies, Lonza said on Tuesday.

ZURICH, Aug 4 (Reuters) - Swiss contract manufacturer Lonza Group LONN.S is adding a mid-scale microbial facility to supply France's Laboratoires Servier with active pharmaceutical ingredient for acute lymphoblastic leukaemia therapies, Lonza said on Tuesday.

The new facility will go online in the second half of 2022, with 100 new staff to be recruited, Lonza added in a statement.

(Reporting by Michael Shields Editing by Michelle Martin)

((Michael.Shields@thomsonreuters.com; +41 58 306 7461; Reuters Messaging: michael.shields.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More